CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
- Name
- CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
- Accession Number
- DBCAT005665
- Description
Type of immunotherapy that involves the adoptive transfer of T cells that have been genetically modified with a chimeric antigen receptor (CAR) to target CD19.
- Drugs
Drug Drug Description Brexucabtagene autoleucel A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. Lisocabtagene maraleucel A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas. - Drugs & Drug Targets
Drug Target Type Brexucabtagene autoleucel B-lymphocyte antigen CD19 target Lisocabtagene maraleucel B-lymphocyte antigen CD19 target